Odyssey Therapeutics (ODTX) Stock Price, News & Analysis

Company Overview

Odyssey Therapeutics Inc. is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc. is based in BOSTON.

Key Stats

• Today's Range: $24.55 to $26.49
• 50-Day Range: $15.56 to $26.39
• 52-Week Range: $15.10 to $26.49
• Volume: 181,273 shs
• Average Volume: 290,562 shs
• Market Capitalization: $1.27 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $33.00
• Consensus Rating: Moderate Buy

Odyssey Therapeutics Stock Analysis - MarketRank™

Odyssey Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 430th out of 914 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Odyssey Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Odyssey Therapeutics has a consensus price target of $33.00, representing about 25.0% upside from its current price of $26.39.

Amount of Analyst Coverage

Odyssey Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Odyssey Therapeutics are expected to grow in the coming year, from ($5.97) to ($4.94) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Odyssey Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Odyssey Therapeutics is -3.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Odyssey Therapeutics has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.73% of the float of Odyssey Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Odyssey Therapeutics has a short interest ratio ("days to cover") of 9.68.

Change versus previous month

Short interest in Odyssey Therapeutics has recently increased by 13.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Odyssey Therapeutics does not currently pay a dividend.

Dividend Growth

Odyssey Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Odyssey Therapeutics this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for ODTX on MarketBeat in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Odyssey Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Institutions

Odyssey Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 8/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ODTX
• CIK: 1882782
• Web: odysseytx.com
• Phone: 617-865-9628
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Odyssey Therapeutics: $33.00
• High Price Target: $40.00
• Low Price Target: $29.00
• Potential Upside/Downside: +25.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.36
• Quick Ratio: 11.36

Sales & Book Value

• Annual Sales: $99 thousand
• Price / Sales: 12,810.88
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.76 per share
• Price / Book: 3.01

Miscellaneous

• Outstanding Shares: 48,059,000
• Free Float: N/A
• Market Cap: $1.27 billion
• Optionable: N/A
• Beta: N/A